QR Kod

The impact of lenvatinib on sarcopenia in patients with advanced unresectable hepatocellular carcinoma

Abstract Lenvatinib is a multiple receptor tyrosine kinase inhibitor (TKI) approved for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). TKI are suspected of exacerbating muscle loss in patients with cancer. In this study, we analyze the role of muscle loss in patie...

Ful tanımlama

Kaydedildi:
Asıl Yazarlar: Michael Praktiknjo, Ana S. Pena Solano, Farsaneh Sadeghlar, Thomas Welchowski, Matthias Schmid, Christian Möhring, Taotao Zhou, Robert Mahn, Malte B. Monin, Carsten Meyer, Georg Feldmann, Peter Brossart, Cornelius van Beekum, Alexander Semaan, Hanno Matthaei, Steffen Manekeller, Alois M. Sprinkart, Sebastian Nowak, Julian Luetkens, Jörg C. Kalff, Christian P. Strassburg, Maria A. González-Carmona
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Portfolio 2024-09-01
Seri Bilgileri:Scientific Reports
Online Erişim:https://doi.org/10.1038/s41598-024-66766-8
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller